Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer by Ruoshuang Han, Haoyue Guo, Jinpeng Shi, Sha Zhao, Yijun Jia, Xiaozhen Liu, Yiwei Liu, Lei Cheng, Chao Zhao, Xuefei Li, Caicun Zhou

Get full text

Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer by Ruoshuang Han, Haoyue Guo, Jinpeng Shi, Sha Zhao, Yijun Jia, Xiaozhen Liu, Yiwei Liu, Lei Cheng, Chao Zhao, Xuefei Li, Caicun Zhou

Get full text

Could tumor spread through air spaces benefit from adjuvant chemotherapy in stage I lung adenocarcinoma? A multi-institutional study by Donglai Chen, Xiaofan Wang, Fuquan Zhang, Ruoshuang Han, Qifeng Ding, Xuejun Xu, Jian Shu, Fei Ye, Li Shi, Yiming Mao, Yongbing Chen, Chang Chen

Get full text

Patients With Short PFS to EGFR-TKIs Predicted Better Response to Subsequent Anti-PD-1/PD-L1 Based Immunotherapy in EGFR Common Mutation NSCLC by Sangtian Liu, Fengying Wu, Xuefei Li, Chao Zhao, Yijun Jia, Keyi Jia, Ruoshuang Han, Meng Qiao, Wei Li, Jia Yu, Fei Zhou, Anwen Xiong, Bin Chen, Jue Fan, Shengxiang Ren, Caicun Zhou

Get full text